EOG Resources Inc vs Inovio Pharmaceuticals Inc — how do they compare? EOG Resources Inc trades at $142.4 (market cap $75.22B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: EOG Resources Inc is far larger — about 957.6× Inovio Pharmaceuticals Inc's market cap, and EOG Resources Inc pays a 2.85% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EOG | INO | |
|---|---|---|
Market Cap | $75.22B | $78.55M |
Sector | Energy | Health |
52-Week High | $149.89 | $2.87 |
52-Week Low | $101.78 | $0.66 |
Enterprise Value | $78.56B | $49.56M |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $142.22, up 5.55% today, with strong earnings beats in recent quarters and a bullish technical signal. The stock shows robust profitability with a 25.81% net income margin and attractive valuation metrics, including a P/E of 11.16. Recent news highlights operational strength and institutional buying interest, supporting positive momentum.
The outlook remains favorable with a consensus price target of $157.88, indicating potential upside. Key risks include oil price volatility and capital expenditure intensity, but disciplined cost controls and shareholder returns provide stability. The stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →